Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Research Article

Role of miRNA-99a-5p in Modulating the Function of Hepatocellular Carcinoma Cells: Bioinformatics Analysis and In Vitro Assay

Author(s): Jia-Ning Zhang, Feng Wei, Bin Bin Zheng, Liang Tang* and Feng-Yuan Chen*

Volume 23, Issue 6, 2023

Published on: 02 March, 2023

Page: [461 - 470] Pages: 10

DOI: 10.2174/1568009623666230202155440

Price: $65

Abstract

Aim: This study aimed to investigate the biological functions of miRNAs in hepatobiliary tumors as the focus of targeted therapy research.

Background: Hepatobiliary tumors are among the leading causes of cancer-related deaths worldwide. Many microRNAs (miRNAs) play an important regulatory role in tumor progression. Our study aims to explore some biologically functional miRNAs from different datasets of hepatobiliary tumors for disease diagnosis or treatment.

Objective: In this study, we tried to filter out differentially expressed miRNAs in different tumor datasets from the GEO database.

Methods: In this study, we first perform analyses in different GEO data sets. After taking the intersection, the initial scope is limited to several differential RNAs. Then, combined with the existing research results from Kaplan-Meier survival analysis and literature, the candidate molecule was finally identified to be studied. Furthermore, the biological characteristics analysis of the candidate molecule was performed on the basis of Cancermirnome online tool, including expression levels in tumors, KEGG and GO analysis, ROC analysis, and target gene prediction. Furthermore, the effect of the candidate molecule on the biological functions of liver cancer was verified by In Vitro assay.

Results: The preliminary analysis of bioinformatics shows that 16 differentially expressed miRNAs may play an important role in HCC or ICC. Ultimately, we identified miRNA-99a-5p as the only molecule to study. The results showed that miRNA-99a-5p is abnormally expressed in many tumors, and in liver cancer, its level of expression in tumor tissue is significantly lower than that in normal tissue. Then, the KEGG and GO analysis found that it functions in multiple pathways. At the same time, the ROC analysis found that it showed great potential for prognostic prediction in HCC and we also predicted that RUNDC3B is the most likely target to which it binds. Finally, the experimental results of overexpression and knockdown confirmed that miRNA-99a-5p could inhibit cell proliferation in HCC, which also suggested that it may be an important tumor suppressor in HCC.

Conclusion: MiRNA-99a-5p was negatively correlated with HCC progression and could act as a novel therapeutic target for HCC.

Graphical Abstract

[1]
Massarweh, N.N.; El-Serag, H.B. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Contr., 2017, 24(3)1073274817729245
[http://dx.doi.org/10.1177/1073274817729245] [PMID: 28975830]
[2]
Llovet, J.M.; Pinyol, R.; Kelley, R.K.; El-Khoueiry, A.; Reeves, H.L.; Wang, X.W.; Gores, G.J.; Villanueva, A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat. Can., 2022, 3(4), 386-401.
[http://dx.doi.org/10.1038/s43018-022-00357-2] [PMID: 35484418]
[3]
Hewitt, D.B.; Brown, Z.J.; Pawlik, T.M. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev. Anticancer Ther., 2022, 22(1), 27-38.
[http://dx.doi.org/10.1080/14737140.2022.1999809] [PMID: 34730474]
[4]
Xu, L.; Huang, X.; Lou, Y.; Xie, W.; Zhao, H. Regulation of apoptosis, autophagy and ferroptosis by non coding RNAs in metastatic non small cell lung cancer. Review Exp. Ther. Med., 2022, 23(5), 352.
[http://dx.doi.org/10.3892/etm.2022.11279] [PMID: 35493430]
[5]
Roy, R.K.; Yadav, R.; Sharma, U.; Wasson, M.K.; Sharma, A.; Tanwar, P.; Jain, A.; Prakash, H. Impact of noncoding RNAS on cancer directed immune therapies: Now then and forever. Int. J. Cancer, 2022, 151(7), 981-992.
[http://dx.doi.org/10.1002/ijc.34060] [PMID: 35489027]
[6]
Zhou, Z.; Wang, Z.; Gao, J.; Lin, Z.; Wang, Y.; Shan, P.; Li, M.; Zhou, T.; Li, P. Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma. Mol. Ther. Oncolytics, 2022, 25, 98-120.
[http://dx.doi.org/10.1016/j.omto.2022.03.002] [PMID: 35506150]
[7]
Li, Z.; Shen, J.; Chan, M.T.V.; Wu, W.K.K. The role of microRNAs in intrahepatic cholangiocarcinoma. J. Cell. Mol. Med., 2017, 21(1), 177-184.
[http://dx.doi.org/10.1111/jcmm.12951] [PMID: 27619971]
[8]
Lee, Y.S.; Dutta, A. MicroRNAs in Cancer. Annu. Rev. Pathol., 2009, 4(1), 199-227.
[http://dx.doi.org/10.1146/annurev.pathol.4.110807.092222] [PMID: 18817506]
[9]
Tiwari, A.; Mukherjee, B.; Dixit, M. MicroRNA key to angiogenesis regulation: MiRNA biology and therapy. Curr. Cancer Drug Targets, 2018, 18(3), 266-277.
[http://dx.doi.org/10.2174/1568009617666170630142725] [PMID: 28669338]
[10]
Mishra, S.; Yadav, T.; Rani, V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit. Rev. Oncol. Hematol., 2016, 98, 12-23.
[http://dx.doi.org/10.1016/j.critrevonc.2015.10.003] [PMID: 26481951]
[11]
Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov., 2017, 16(3), 203-222.
[http://dx.doi.org/10.1038/nrd.2016.246] [PMID: 28209991]
[12]
Sun, Y.; Chen, G.; He, J.; Huang, Z.G.; Li, S.H.; Yang, Y.P.; Zhong, L.Y.; Ji, S.F.; Huang, Y.; Chen, X.H.; He, M.L.; Wu, H. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer. Bioengineered, 2021, 12(1), 325-340.
[http://dx.doi.org/10.1080/21655979.2020.1867405] [PMID: 33356818]
[13]
Liu, G.; Lei, Y.; Luo, S.; Huang, Z.; Chen, C.; Wang, K.; Yang, P.; Huang, X. MicroRNA expression profile and identification of novel microRNA biomarkers for metabolic syndrome. Bioengineered, 2021, 12(1), 3864-3872.
[http://dx.doi.org/10.1080/21655979.2021.1952817] [PMID: 34269146]
[14]
Li, R.; Qu, H.; Wang, S.; Chater, J.M.; Wang, X.; Cui, Y.; Yu, L.; Zhou, R.; Jia, Q.; Traband, R.; Wang, M.; Xie, W.; Yuan, D.; Zhu, J.; Zhong, W.D.; Jia, Z. CancerMIRNome: An interactive analysis and visualization database for miRNome profiles of human cancer. Nucleic Acids Res., 2022, 50(D1), D1139-D1146.
[http://dx.doi.org/10.1093/nar/gkab784] [PMID: 34500460]
[15]
Hua, S.; Quan, Y.; Zhan, M.; Liao, H.; Li, Y.; Lu, L. miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1. Cancer Cell Int., 2019, 19(1), 203.
[http://dx.doi.org/10.1186/s12935-019-0919-6] [PMID: 31384178]
[16]
Fang, F.; Chang, R.; Yu, L.; Lei, X.; Xiao, S.; Yang, H.; Yang, L.Y. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J. Hepatol., 2015, 63(4), 874-885.
[http://dx.doi.org/10.1016/j.jhep.2015.05.008] [PMID: 25998163]
[17]
Chen, L.; Heikkinen, L.; Wang, C.; Yang, Y.; Sun, H.; Wong, G. Trends in the development of miRNA bioinformatics tools. Brief. Bioinform., 2019, 20(5), 1836-1852.
[http://dx.doi.org/10.1093/bib/bby054] [PMID: 29982332]
[18]
Lu, T.X.; Rothenberg, M.E. MicroRNA. J. Allergy Clin. Immunol., 2018, 141(4), 1202-1207.
[http://dx.doi.org/10.1016/j.jaci.2017.08.034] [PMID: 29074454]
[19]
Hill, M.; Tran, N. miRNA interplay: Mechanisms and consequences in cancer. Dis. Model. Mech., 2021, 14(4)dmm047662
[http://dx.doi.org/10.1242/dmm.047662] [PMID: 33973623]
[20]
Shi, Y.; Zhang, D.D.; Liu, J.B.; Yang, X.L.; Xin, R.; Jia, C.Y.; Wang, H.M.; Lu, G.X.; Wang, P.Y.; Liu, Y.; Li, Z.J.; Deng, J.; Lin, Q.L.; Ma, L.; Feng, S.S.; Chen, X.Q.; Zheng, X.M.; Zhou, Y.F.; Hu, Y.J.; Yin, H.Q.; Tian, L.L.; Gu, L.P.; Lv, Z.W.; Yu, F.; Li, W.; Ma, Y.S.; Da, F. Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma. Mol. Ther. Nucleic Acids, 2021, 23, 702-718.
[http://dx.doi.org/10.1016/j.omtn.2020.12.016] [PMID: 33575116]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy